Jennifer E. Amengual

2.3k total citations
87 papers, 1.1k citations indexed

About

Jennifer E. Amengual is a scholar working on Molecular Biology, Pathology and Forensic Medicine and Oncology. According to data from OpenAlex, Jennifer E. Amengual has authored 87 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 47 papers in Molecular Biology, 43 papers in Pathology and Forensic Medicine and 37 papers in Oncology. Recurrent topics in Jennifer E. Amengual's work include Lymphoma Diagnosis and Treatment (43 papers), Histone Deacetylase Inhibitors Research (24 papers) and Protein Degradation and Inhibitors (16 papers). Jennifer E. Amengual is often cited by papers focused on Lymphoma Diagnosis and Treatment (43 papers), Histone Deacetylase Inhibitors Research (24 papers) and Protein Degradation and Inhibitors (16 papers). Jennifer E. Amengual collaborates with scholars based in United States, Australia and United Kingdom. Jennifer E. Amengual's co-authors include Jennifer Kimberly Lue, Owen A. O’Connor, Luigi Scotto, Serge Cremers, Enrica Marchi, Ahmed Sawas, Matko Kalac, Changchun Deng, Kelly Zullo and Govind Bhagat and has published in prestigious journals such as Nature Communications, Journal of Clinical Oncology and Blood.

In The Last Decade

Jennifer E. Amengual

84 papers receiving 1.0k citations

Peers

Countries citing papers authored by Jennifer E. Amengual

Since Specialization

Citations

This map shows the geographic impact of Jennifer E. Amengual's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jennifer E. Amengual with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jennifer E. Amengual more than expected).

Fields of papers citing papers by Jennifer E. Amengual

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jennifer E. Amengual. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jennifer E. Amengual. The network helps show where Jennifer E. Amengual may publish in the future.

Co-authorship network of co-authors of Jennifer E. Amengual

This figure shows the co-authorship network connecting the top 25 collaborators of Jennifer E. Amengual. A scholar is included among the top collaborators of Jennifer E. Amengual based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jennifer E. Amengual. Jennifer E. Amengual is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Ruxolitinib increases immunogenicity and primes the tumor microenvironment for immune checkpoint blockade in 9p24.1 amplified lymphomas 2025 ·Blood ·Seda S. Tolu, (unknown), Manuel Pazos, (unknown), Aleksandar Obradović, (unknown), Barbara Pro, Jennifer E. Amengual	0
2	New approach to specific Alzheimer's disease diagnosis based on plasma biomarkers in a cognitive disorder cohort 2025 ·European Journal of Clinical Investigation ·(unknown), (unknown), Carmen Peña‐Bautista, (unknown), Jennifer E. Amengual, Miquel Baquero, Laura Cubas-Núñez, Bonaventura Casanova, Consuelo Cháfer‐Pericás	1
3	Dual HDAC and EZH2 Inhibition Primes Mosunetuzumab for the Treatment of Germinal Center-Derived B-Cell Lymphoma 2024 ·Blood ·(unknown), (unknown), Manuel Pazos, (unknown), Seda S. Tolu, Jennifer E. Amengual	1
4	Etctn P10500: Phase 1 Study of Tazemetostat Plus Belinostat for the Treatment of Relapsed or Refractory Lymphoma 2024 ·Blood ·Jennifer E. Amengual, Aung M. Tun, (unknown), (unknown), Victor Yazbeck, (unknown), Seda S. Tolu, Barbara Pro, Diane E. Durecki, Jan H. Beumer, Neil L. Kelleher, (unknown), (unknown), (unknown), (unknown), Yu Shyr, Patricia LoRusso, Lorraine Pelosof, Richard Piekarz	2
5	Combination JAK Inhibition and Immune Checkpoint Blockade for the Treatment of 9p Amplified Lymphomas 2024 ·Blood ·Seda S. Tolu, (unknown), Manuel Pazos, (unknown), (unknown), Barbara Pro, Jennifer E. Amengual	1
6	How I treat posttransplant lymphoproliferative disorder 2023 ·Blood ·Jennifer E. Amengual, Barbara Pro	11
7	Context-defined cancer co-dependency mapping identifies a functional interplay between PRC2 and MLL-MEN1 complex in lymphoma 2023 ·Nature Communications ·Xiao Chen, Yinglu Li, Fang Zhu, Xinjing Xu, (unknown), (unknown), John T. McGuire, Dimitris Karagiannis, Varun Sahu, (unknown), Claudio Scuoppo, Francisco J. Sánchez‐Rivera, Yadira M. Soto‐Feliciano, Laura Pasqualucci, Alberto Ciccia, Jennifer E. Amengual, Chao Lü	12
8	S2207: RANDOMIZED PHASE II STUDY OF THE ADDITION OF TARGETED AGENTS TO TAFASITAMAB‐LENALIDOMIDE IN TRANSPLANT INELIGIBLE PATIENTS WITH RELAPSED/REFRACTORY LBCL 2023 ·Hematological Oncology ·Jennifer E. Amengual, Patrick M. Reagan, (unknown), Hayder Saeed, Riha Vaidya, Joseph M. Unger, Alexey V. Danilov, Michael LeBlanc, Jonathan W. Friedberg, Sonali M. Smith	1
9	Precision Targeting with EZH2 and HDAC Inhibitors in Epigenetically Dysregulated Lymphomas 2019 ·Clinical Cancer Research ·Jennifer Kimberly Lue, Sathyen A. Prabhu, Yuxuan Liu, (unknown), Akanksha Verma, Prabhjot S. Mundi, Nebiyu Abshiru, Jeannie M. Camarillo, (unknown), (unknown), (unknown), Renu Nandakumar, Serge Cremers, Neil L. Kelleher, Olivier Elemento, Jennifer E. Amengual	59
10	Chromatin-Remodeled State in Lymphoma 2019 ·Current Hematologic Malignancy Reports ·Yuxuan Liu, (unknown), Jennifer E. Amengual	5
11	The Future of Combination Therapies for Peripheral T Cell Lymphoma (PTCL) 2018 ·Current Hematologic Malignancy Reports ·Helen Ma, Ardalan Davarifar, Jennifer E. Amengual	22
12	A phase 1/2 trial of ublituximab, a novel anti‐ CD 20 monoclonal antibody, in patients with B‐cell non‐Hodgkin lymphoma or chronic lymphocytic leukaemia previously exposed to rituximab 2017 ·British Journal of Haematology ·Ahmed Sawas, Charles M. Farber, Marshall T. Schreeder, (unknown), Daruka Mahadevan, Changchun Deng, Jennifer E. Amengual, Petros Nikolinakos, Jill Kolesar, John G. Kuhn, Peter Sportelli, Hari P. Miskin, Owen A. O’Connor	61
13	A phase 1 study of romidepsin and pralatrexate reveals marked activity in relapsed and refractory T-cell lymphoma 2017 ·Blood ·Jennifer E. Amengual, (unknown), Jennifer Kimberly Lue, Ahmed Sawas, Changchun Deng, (unknown), (unknown), (unknown), Aishling M. Rada, (unknown), Codruța Chiuzan, Matko Kalac, Enrica Marchi, Lorenzo Falchi, (unknown), Lawrence Schwartz, Serge Cremers, Owen A. O’Connor	91
14	A Phase 1/2 Study of Oral 5-Azacitidine and Romidepsin in Patients with Lymphoid Malignancies Reveals Promising Activity in Heavily Pretreated Peripheral T-Cell Lymphoma (PTCL) 2017 ·Blood ·Lorenzo Falchi, Jennifer Kimberly Lue, Jennifer E. Amengual, Ahmed Sawas, Changchun Deng, Enrica Marchi, (unknown), (unknown), (unknown), (unknown), Aishling M. Rada, (unknown), (unknown), Owen A. O’Connor	10
15	Mechanisms of Acquired Drug Resistance to the HDAC6 Selective Inhibitor Ricolinostat Reveals Rational Drug-Drug Combination with Ibrutinib 2016 ·Clinical Cancer Research ·Jennifer E. Amengual, Sathyen A. Prabhu, Maximilian Lombardo, Kelly Zullo, Paul Johannet, (unknown), Luigi Scotto, (unknown), (unknown), Jimmy Duong, Renu Nandakumar, Serge Cremers, Akanksha Verma, Olivier Elemento, Owen A. O’Connor	24
16	Preclinical Pharmacologic Evaluation of Pralatrexate and Romidepsin Confirms Potent Synergy of the Combination in a Murine Model of Human T-cell Lymphoma 2015 ·Clinical Cancer Research ·Salvia Jain, (unknown), Kelly Zullo, Luigi Scotto, Carmine F. Palermo, Stephen A. Sastra, Kenneth P. Olive, Serge Cremers, Tiffany Thomas, (unknown), Yuan Zhang, Govind Bhagat, Jennifer E. Amengual, Changchun Deng, Charles Karan, Ronald Realubit, Susan E. Bates, Owen A. O’Connor	49
17	Dual Targeting of Protein Degradation Pathways with the Selective HDAC6 Inhibitor ACY-1215 and Bortezomib Is Synergistic in Lymphoma 2015 ·Clinical Cancer Research ·Jennifer E. Amengual, Paul Johannet, Maximilian Lombardo, Kelly Zullo, Daniela Hoehn, Govind Bhagat, Luigi Scotto, (unknown), Dejan Radeski, (unknown), Hongfeng Jiang, Serge Cremers, Yuan Zhang, Simon Jones, Owen A. O’Connor	71
18	Aurora A Kinase Inhibition Selectively Synergizes with Histone Deacetylase Inhibitor through Cytokinesis Failure in T-cell Lymphoma 2015 ·Clinical Cancer Research ·Kelly Zullo, (unknown), Laurence Cooke, (unknown), (unknown), Luigi Scotto, Jennifer E. Amengual, Yinghui Mao, Renu Nandakumar, Serge Cremers, Jimmy Duong, Daruka Mahadevan, Owen A. O’Connor	33
19	Will new drugs change the standard of care for patients with mantle cell lymphoma? 2015 ·Expert Review of Anticancer Therapy ·(unknown), Jennifer E. Amengual, Changchun Deng, Ahmed Sawas, Owen A. O’Connor	1
20	Development and Characterization of a Novel CD19CherryLuciferase (CD19CL) Transgenic Mouse for the Preclinical Study of B-Cell Lymphomas 2012 ·Clinical Cancer Research ·Luigi Scotto, Marianna Kruithof‐de Julio, Luca Paoluzzi, Matko Kalac, Enrica Marchi, (unknown), Jennifer E. Amengual, Michael M. Shen, Owen A. O’Connor	10

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact